ArriVent BioPharma, Inc. (AVBP)
NASDAQ: AVBP · Real-Time Price · USD
27.45
+0.86 (3.23%)
Nov 22, 2024, 4:00 PM EST - Market closed
ArriVent BioPharma Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
40
Market Cap
924.99M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionAVBP News
- 2 months ago - ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer - GlobeNewsWire
- 3 months ago - Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma - Business Wire
- 3 months ago - ArriVent BioPharma Reports Second Quarter 2024 Financial Results - GlobeNewsWire
- 3 months ago - ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer - GlobeNewsWire
- 6 months ago - ArriVent Announces a Multi-Target ADC Collaboration with Alphamab - GlobeNewsWire
- 6 months ago - ArriVent Appoints John Hohneker, M.D., to its Board of Directors - GlobeNewsWire
- 7 months ago - ArriVent BioPharma Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 7 months ago - ArriVent Appoints Kristine Peterson to its Board of Directors - GlobeNewsWire